Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas.
OBJECTIVE
To determine if goserelin immediately after uterine artery embolization (UAE) affected myoma reduction.


METHODS
Randomized pilot study (level 1).


METHODS
Teaching hospital.


METHODS
Twenty-six women.


METHODS
All patients underwent UAE, and then 12 patients received 10.8 mg of goserelin 24 hours later. The treatment group was 5 years older: 43 versus 37.7 years. Uterine and myoma volumes were measured by ultrasound 2 weeks before UAE and at 3, 6, and 12 months.


METHODS
Uterine and fibroid volumes.


RESULTS
Pretreatment uterine volume was 477 versus 556 cm3, and dominant fibroid volume was 257 versus 225 cm3 in the control versus goserelin groups. Analysis of variance measurements indicated that the change over time did not significantly differ between the two groups. By 12 months, the control group had a mean uterine volume reduction of 58%, while the goserelin group had a reduction of 45%. Dominant fibroid changes over time did not differ between the two groups. At 12 months, the mean fibroid volume had decreased by 86% and 58% in the control and goserelin groups, respectively.


CONCLUSIONS
The addition of goserelin therapy to UAE did not alter the reduction rate or volume of uterine myomas.
Vilos
George A
GA
Department of Obstetrics and Gynecology, St. Joseph's Health Care, University of Western Ontario, London, Ontario, Canada.
Vilos
Angelos G
AG
Abu-Rafea
Basim
B
Pron
Gaylene
G
Kozak
Roman
R
Garvin
Greg
G
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D004621:Embolization, Therapeutic / Q000706:statistics & numerical data*; D005260:Female; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D007889:Leiomyoma / Q000098:blood supply / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*; D009864:Ontario / Q000453:epidemiology; D010865:Pilot Projects; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000098:blood supply / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*
D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin